Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
15.10. | Celltrion unveils promising dose escalation results for subcutaneous infliximab | ||
15.10. | Alleo and Ubiquigent unite to accelerate drug discovery | ||
14.10. | Lundbeck to acquire Longboard Pharmaceuticals in strategic deal | ||
14.10. | Transgene's cancer vaccine trial shows mixed results | ||
10.10. | Heart patient goes home hours after live-streamed valve replacement | ||
10.10. | Johnson & Johnson myeloma drug recommended for NHS use | ||
09.10. | Purespring Therapeutics secures £80 million in Series B funding | ||
09.10. | Sanofi launches high-dose flu vaccine in the UK | ||
08.10. | Kyowa Kirin announces positive interim data for lymphoma treatment | ||
08.10. | Astellas and AviadoBio announce exclusive gene therapy deal | ||
07.10. | FluoGuide submits clinical trial application for head and neck cancer treatment | ||
07.10. | Scottish patients first in UK to access new lung cancer treatment | ||
03.10. | IRLAB's new drug shows promise in treating apathy in Parkinson's patients | ||
03.10. | ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study | ||
02.10. | Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy | ||
02.10. | AlzeCure's abstract on ACD856's effects to be presented at Alzheimer's conference | ||
01.10. | European Commission approves yuvanci for pulmonary arterial hypertension treatment | ||
26.09. | Sheffield A&E to implement life-saving HIV and hepatitis testing | ||
26.09. | Oxford drug design secures funding to combat cystic fibrosis lung infections | ||
24.09. | Cancer Grand Challenges launches global initiative to take on toughest problems | ||
24.09. | AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment | ||
19.09. | Oncologica to advance urine-based prostate cancer screening test | ||
18.09. | NHS Trust to evaluate AI software for prostate cancer diagnosis | ||
18.09. | FlyPharma Europe, Vienna - October 2024 conference | ||
17.09. | UKRI's MRC awards £27.4m to University of Dundee research unit |